Bivalirudin use in patients undergoing percutaneous coronary intervention for acute myocardial infarction. Insights from the prospective, multi-centre EUROVISION registry

References

• Stone GW, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, Moses JW, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med. 2006;355:2203–16.
   PubMed Web of Science ®Google Scholar
• Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med. 2008;358:2218–30.
   PubMed Web of Science ®Google Scholar
• Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, et al. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): Final 3-year results from a multicentre, randomised controlled trial. Lancet 2011;377:2193–204.
   PubMed Web of Science ®Google Scholar
• Mehran R, Lansky AJ, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, et al. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. Lancet 2009; 374:1149–59.
   PubMed Web of Science ®Google Scholar
• Steg PG, James SK, Atar D, Badano LP, Blomstrom-Lundqvist C, Borger MA, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33:2569–619.
   PubMed Web of Science ®Google Scholar
• Steg PG, van 't Hof A, Hamm CW, Clemmensen P, Lapostolle F, Coste P, et al. Bivalirudin started during emergency transport for primary PCI. N Engl J Med. 2013;369:2207–17.
   PubMed Web of Science ®Google Scholar
• Hordijk-Trion M, Lenzen M, Wijns W, de Jaegere P, Simoons ML, Scholte op Reimer WJ, et al. Patients enrolled in coronary intervention trials are not representative of patients in clinical practice: Results from the Euro heart survey on coronary revascularization. Eur Heart J. 2006;27:671–8.
   PubMed Web of Science ®Google Scholar
• Franciosa JA. The potential role of community-based registries to complement the limited applicability of clinical trial results to the community setting: Heart failure as an example. Am J Manag Care 2004;10:487–92.
   PubMedGoogle Scholar
• Jolly SS, Yusuf S, Cairns J, Niemela K, Xavier D, Widimsky P, et al. Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): A randomised, parallel group, multicentre trial. Lancet 2011;377: 1409–20.
   PubMed Web of Science ®Google Scholar
• Romagnoli E, Biondi-Zoccai G, Sciahbasi A, Politi L, Rigattieri S, Pendenza G, et al. Radial versus femoral randomized investigation in ST-segment elevation acute coronary syndrome: The RIFLE-STEACS (radial versus femoral randomized investigation in ST-elevation acute coronary syndrome) study. J Am Coll Cardiol. 2012;60:2481–9.
   PubMed Web of Science ®Google Scholar
• Montalescot G, Wiviott SD, Braunwald E, Murphy SA, Gibson CM, McCabe CH, et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): Double-blind, randomised controlled trial. Lancet 2009;373:723–31.
   PubMed Web of Science ®Google Scholar
• Steg PG, James S, Harrington RA, Ardissino D, Becker RC, Cannon CP, et al. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A platelet inhibition and patient outcomes (PLATO) trial subgroup analysis. Circulation 2010;122:2131–41.
   PubMed Web of Science ®Google Scholar
• Cortese B, Limbruno U, Severi S, De Matteis S, Diehl L, Piti A. Effect of prolonged Bivalirudin infusion on ST-segment resolution following primary percutaneous coronary intervention (from the PROBI VIRI 2 study). Am J Cardiol. 2011;108:1220–4.
   Google Scholar
• Cortese B, Picchi A, Micheli A, Ebert AG, Parri F, Severi S, et al. Comparison of prolonged bivalirudin infusion versus intraprocedural in preventing myocardial damage after percutaneous coronary intervention in patients with angina pectoris. Am J Cardiol. 2009;104:1063–8.
   Google Scholar
• Mueller E, Prabhu W, Desarno M, Sundaran P, Dauerman H. Bleeding complications with regional adaptation of a prolonged bivalirudin regimen for ST-elevation acute myocardial infarction. Am J Cardiol. 2012;110:1607–12.
   Google Scholar
• Hamon M, Nienaber CA, Galli S, Huber K, Lipiecki J, Hill JM, et al. Bivalirudin in percutaneous coronary intervention: the EUROpean BiValIrudin UtiliSatION in Practice (EUROVISION) Registry. Int J Cardiol. 2014;173:290–4.
   Google Scholar
• World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. J Am Med Assoc. 2000;284(23):3043–5.
   PubMed Web of Science ®Google Scholar
• Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, et al. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation 2007;115: 2344–51.
   PubMed Web of Science ®Google Scholar
• Schiele F, Hochadel M, Tubaro M, Meneveau N, Wojakowski W, Gierlotka M, et al. Reperfusion strategy in Europe: Temporal trends in performance measures for reperfusion therapy in ST-elevation myocardial infarction. Eur Heart J. 2010;31:2614–24.
   PubMedGoogle Scholar
• Busch G, Steppich B, Sibbing D, Braun SL, Stein A, Groha P, et al. Bivalirudin reduces platelet and monocyte activation after elective percutaneous coronary intervention. Thromb Haemost. 2009;101:340–4.
   PubMed Web of Science ®Google Scholar
• Valgimigli M, Tebaldi M, Campo G, Gambetti S, Bristot L, Monti M, et al. Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: The FABOLUS PRO (facilitation through aggrastat by dropping or shortening infusion line in patients with ST-segment elevation myocardial infarction compared to or on top of prasugrel given at loading dose) trial. JACC Cardiovasc Interv. 2012;5:268–77.
   PubMed Web of Science ®Google Scholar
• Dangas GD, Mehran R, Nikolsky E, Claessen BE, Lansky AJ, Brodie BR, et al. Effect of switching antithrombin agents for primary angioplasty in acute myocardial infarction: The HORIZONS-SWITCH analysis. J Am Coll Cardiol. 2011;57:2309–16.
   PubMed Web of Science ®Google Scholar
• Koutouzis M, Lagerqvist B, James S, Omerovic E, Matejka G, Grip L, et al. Unfractionated heparin administration in patients treated with bivalirudin during primary percutaneous coronary intervention is associated lower mortality and target lesion thrombosis: A report from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Heart 2011;97:1484–8.
   PubMed Web of Science ®Google Scholar